Abstract
Syed Hasan Raza, Zachary Nuffer, Neal Savjani, Ayman Farag, Arash Kardan
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Hepatocellular carcinoma: a comprehensive review.
10.3390/diseases13070207 · 2025
Cancer statistics, 2026.
2026
Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022.
10.1016/j.scib.2025.12.022 · 2026
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
10.1016/s0140-6736(25)01042-6 · 2025
Hepatocellular carcinoma.
10.1093/ajcp/aqab125 · 2021
Surgery and portal hypertension.
1964
Transection of the oesophagus for bleeding oesophageal varices.
10.1002/bjs.1800600817 · 1973
Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients.
10.1186/s13550-016-0212-9 · 2016
The evolution in the prioritization for liver transplantation.
2012
Assessment of prognosis of cirrhosis.
10.1055/s-2008-1040325 · 2008
Model for end-stage liver disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis.
10.1016/j.amjsurg.2007.05.054 · 2008
Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications.
10.1111/j.1399-0012.2005.00463.x · 2006
Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal.
10.1016/j.jhep.2024.01.010 · 2024
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
10.1111/j.1600-6143.2009.02695.x · 2009
Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes.
10.1053/j.gastro.2009.09.006 · 2010
Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin–99mTc-sulfur colloid SPECT.
10.2967/jnumed.113.123257 · 2013
Differential hepatic avoidance radiation therapy: proof of concept in hepatocellular carcinoma patients.
10.1016/j.radonc.2015.04.011 · 2015
Assessment of functional liver reserve: old and new in 99mTc-sulfur colloid scintigraphy.
10.1097/mnm.0000000000000695 · 2017
Mechanism of hepatic extraction of gelatinized 99m technetium sulfur colloid.
10.1007/bf00271906 · 1980
Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis.
10.3389/fmed.2023.1118531 · 2023
Colloid shift in technetium-99m sulfur colloid liver-spleen scans of trauma patients.
10.1097/00003072-198710000-00010 · 1987
Functional liver imaging and dosimetry to predict hepatotoxicity risk in cirrhotic patients with primary liver cancer.
10.1016/j.ijrobp.2018.08.029 · 2018
Using the albumin-bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma.
10.21037/jgo.2018.05.14 · 2018
Biochemical safety of ablative yttrium-90 radioembolization for hepatocellular carcinoma as a function of percent liver treated.
10.2147/jhc.s319215 · 2021
Functional liver imaging and dosimetry for risk stratification in patients with hepatocellular carcinoma undergoing radiotherapy: validation study.
10.1016/j.radonc.2025.110963 · 2025
Regional radiation dose-response modeling of functional liver in hepatocellular carcinoma patients with longitudinal sulfur colloid SPECT/CT: a proof of concept.
10.1016/j.ijrobp.2018.06.017 · 2018
Liver injury and recovery following radiation therapy for hepatocellular carcinoma: insights from functional liver imaging.
2024
Hepatic decompensation after transarterial radioembolization: a retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.
10.1002/hep4.2072 · 2022
Hepatic decompensation after transarterial radioembolization: a retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.
10.1002/hep4.2072 · doi-reference
Regional radiation dose-response modeling of functional liver in hepatocellular carcinoma patients with longitudinal sulfur colloid SPECT/CT: a proof of concept.
10.1016/j.ijrobp.2018.06.017 · doi-reference
Functional liver imaging and dosimetry for risk stratification in patients with hepatocellular carcinoma undergoing radiotherapy: validation study.
10.1016/j.radonc.2025.110963 · doi-reference
Biochemical safety of ablative yttrium-90 radioembolization for hepatocellular carcinoma as a function of percent liver treated.
10.2147/jhc.s319215 · doi-reference
Using the albumin-bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma.
10.21037/jgo.2018.05.14 · doi-reference
Functional liver imaging and dosimetry to predict hepatotoxicity risk in cirrhotic patients with primary liver cancer.
10.1016/j.ijrobp.2018.08.029 · doi-reference
Colloid shift in technetium-99m sulfur colloid liver-spleen scans of trauma patients.
10.1097/00003072-198710000-00010 · doi-reference
Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis.
10.3389/fmed.2023.1118531 · doi-reference
Mechanism of hepatic extraction of gelatinized 99m technetium sulfur colloid.
10.1007/bf00271906 · doi-reference
Assessment of functional liver reserve: old and new in 99mTc-sulfur colloid scintigraphy.
10.1097/mnm.0000000000000695 · doi-reference
Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin–99mTc-sulfur colloid SPECT.
10.2967/jnumed.113.123257 · doi-reference
Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes.
10.1053/j.gastro.2009.09.006 · doi-reference
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
10.1111/j.1600-6143.2009.02695.x · doi-reference
Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal.
10.1016/j.jhep.2024.01.010 · doi-reference
Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications.
10.1111/j.1399-0012.2005.00463.x · doi-reference
Model for end-stage liver disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis.
10.1016/j.amjsurg.2007.05.054 · doi-reference
Assessment of prognosis of cirrhosis.
10.1055/s-2008-1040325 · doi-reference
Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients.
10.1186/s13550-016-0212-9 · doi-reference
Transection of the oesophagus for bleeding oesophageal varices.
10.1002/bjs.1800600817 · doi-reference
Hepatocellular carcinoma.
10.1093/ajcp/aqab125 · doi-reference
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
10.1016/s0140-6736(25)01042-6 · doi-reference
Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022.
10.1016/j.scib.2025.12.022 · doi-reference
Differential hepatic avoidance radiation therapy: proof of concept in hepatocellular carcinoma patients.
10.1016/j.radonc.2015.04.011 · doi-reference
Hepatocellular carcinoma: a comprehensive review.
10.3390/diseases13070207 · doi-reference